Profound Medical Expands Global Reach with Saudi Arabian Partnership, Navigating Funding Landscape

NEW YORK, NY – November 13, 2025

Expanding Access to Innovative BPH Treatment

Profound Medical Corp. is making strides in the global healthcare market with a newly established distribution agreement for its TULSA PRO system in Saudi Arabia. The partnership with Al Faisaliah Medical Systems, a leading medical device distributor in the region, signals a strategic push to expand access to this innovative treatment for benign prostatic hyperplasia (BPH). This expansion comes as the company continues to navigate the financial challenges inherent in commercializing a novel medical device. TULSA PRO offers a non-surgical alternative to traditional BPH treatments, utilizing real-time MRI guidance for precise thermal ablation of prostate tissue. The increasing prevalence of BPH, coupled with a growing demand for minimally invasive procedures, positions TULSA PRO as a potentially significant player in the urology space.

Navigating a Competitive Landscape and Financial Realities

While the partnership with Al Faisaliah is a positive development, Profound Medical operates in a competitive market with established players offering a range of BPH treatments, including surgical procedures, laser therapies, and other minimally invasive options. The company's success hinges on demonstrating the clinical advantages of TULSA PRO, such as reduced side effects and improved patient outcomes, and effectively communicating these benefits to both physicians and patients. The current focus on expansion is occurring while the company is still in a growth phase, meaning continued investment is needed to drive revenue. “The Saudi Arabian market presents a significant opportunity for TULSA PRO,” noted one industry analyst, “but Profound Medical will need to carefully manage its finances to ensure long-term sustainability.”

Financial Position and Cash Runway

As of September 30, 2025, Profound Medical reported cash and cash equivalents of $24.8 million. However, maintaining a healthy cash position is critical for a company in the commercialization stage, and a clear understanding of the company's burn rate is essential. While revenue has shown growth, the company continues to invest heavily in sales, marketing, and research and development. The ability to effectively scale operations and achieve profitability will determine Profound Medical’s long-term success. Recent data from the company indicates increasing adoption of the TULSA PRO system, with the installed base reaching 70 units and a strong pipeline of qualified sales opportunities. “The current cash position provides a runway for continued expansion, but the company will need to closely monitor expenses and ensure that revenue growth keeps pace,” explained a financial source familiar with the company. The company’s recent regaining of exclusive distribution rights in Canada and additional international partnerships aim to boost sales.

Technology and Clinical Advantages

TULSA PRO stands out from other BPH treatments due to its unique MRI-guided thermal ablation technology. This allows for precise targeting of prostate tissue, minimizing damage to surrounding structures and reducing the risk of side effects. The system’s versatility has also been highlighted, with recent data showcasing its effectiveness in treating a broad spectrum of prostate diseases and severities, including both BPH and prostate cancer. The ongoing collection of real-world clinical data supports the technology’s efficacy and reinforces its potential to become a standard of care for BPH and prostate cancer. Several medical journals have featured research on the benefits of MRI-guided focal therapy for prostate conditions, adding further credibility to the technology. “The precision of MRI guidance is a key differentiator,” commented a practicing urologist. “It allows for a customized ablation that minimizes collateral damage and improves patient outcomes.” The system is now being utilized in various clinics and hospitals worldwide, and the company expects to install at least 75 units by the end of 2025.

Global Expansion and Future Prospects

The partnership with Al Faisaliah Medical Systems represents a strategic move to expand Profound Medical’s global footprint. Saudi Arabia’s growing healthcare infrastructure and increasing demand for advanced medical technologies make it an attractive market for the company. The distribution agreement will allow Profound Medical to reach a wider audience of physicians and patients in the region, increasing awareness and adoption of the TULSA PRO system. Looking ahead, the company is focused on continuing to expand its global reach, driving revenue growth, and achieving profitability. Continued innovation and the development of new applications for its MRI-guided thermal ablation technology are also key priorities. The long-term success of Profound Medical will depend on its ability to effectively navigate the competitive landscape, manage its finances, and deliver innovative solutions that improve the lives of patients with BPH and prostate cancer.